Annexon, Inc.

Overview

"How the company got here": "Annexon, Inc. was founded in 2011 with the goal of developing new medicines by targeting the classical complement pathway, a part of the immune system that can cause inflammation and tissue damage when it malfunctions. The company's scientific approach centers on C1q, a protein that initiates this pathway. By blocking C1q, Annexon aims to stop these damaging inflammatory processes before they start. This focus has led the company to concentrate on diseases affecting the body, brain, and eyes, particularly those with high unmet medical needs. Annexon became a publicly traded company on the Nasdaq stock exchange in 2020, marking a significant milestone in its journey to bring its therapies to patients. The company's strategy has been to build value by demonstrating that inhibiting C1q can be a unique therapeutic approach for severe diseases driven by the classical complement pathway." "What it actually does": "Annexon is a biopharmaceutical company that develops treatments for diseases caused by an overactive part of the immune system called the classical complement pathway. This pathway can mistakenly attack the body's own tissues, leading to inflammation and damage in conditions affecting the nervous system and eyes. Annexon's approach is to block a specific protein, C1q, which is like the 'on switch' for this harmful pathway. By developing drugs that target C1q, Annexon aims to stop these diseases at their source, potentially preventing further tissue damage and improving patient outcomes. The company is currently in the clinical-stage of development, meaning its drug candidates are being tested in human trials to assess their safety and effectiveness." "Tanruprubart (ANX005)": "Annexon's lead drug candidate, tanruprubart (also known as ANX005), is an antibody designed to block C1q and the entire classical complement pathway. It is being developed as a potential treatment for Guillain-Barré syndrome (GBS), a serious autoimmune disorder where the immune system attacks the nerves. Tanruprubart is administered intravenously (through an IV drip) and has completed Phase 3 clinical trials for GBS. The company expects to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for GBS in late 2026, following its review in Europe. The company also investigated tanruprubart for Huntington's disease and amyotrophic lateral sclerosis (ALS), but these programs are not actively listed as current focuses.", "ANX007": "ANX007 is another drug candidate developed by Annexon, designed as an antigen-binding fragment (Fab) that is administered directly into the eye (intravitreally). It is being studied in Phase 3 clinical trials for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that is a leading cause of vision loss in older adults. The goal of ANX007 is to preserve vision, differentiating it from other treatments that primarily focus on slowing the progression of the disease. Annexon is planning to initiate a global pivotal trial for GA in mid-2024, with key data readouts expected in late 2026.", "ANX1502": "Annexon is developing ANX1502, an oral small molecule inhibitor, which is in early-stage (Phase 1) clinical trials. This drug is intended to treat various autoimmune conditions by targeting the complement pathway. The company anticipates releasing proof-of-concept data for ANX1502 in the fall of 2026.", "ANX009": "ANX009 is a drug candidate in Phase 1 clinical trials designed to treat lupus nephritis, a kidney disorder caused by autoimmune disease. It is a C1q-blocking Fab that is administered subcutaneously (under the skin). This therapy aims to disrupt the complement activation triggered by autoantibodies in patients with certain autoimmune diseases.", "What management is betting on now": "Annexon's management is focused on advancing its lead drug candidates, tanruprubart (ANX005) for Guillain-Barré syndrome (GBS) and ANX007 for geographic atrophy (GA), towards potential regulatory approval and commercialization. The company is prioritizing the generation of robust clinical data that demonstrates a meaningful benefit for patients, such as preserving vision or accelerating physical recovery. Annexon is also strengthening its financial position, with a cash runway expected into 2028, to support these critical development milestones. The company is preparing for potential commercial launches by building dedicated teams and refining its go-to-market strategies for both acute and chronic disease indications."